RU2593756C2 - Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе - Google Patents

Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе Download PDF

Info

Publication number
RU2593756C2
RU2593756C2 RU2013138717/04A RU2013138717A RU2593756C2 RU 2593756 C2 RU2593756 C2 RU 2593756C2 RU 2013138717/04 A RU2013138717/04 A RU 2013138717/04A RU 2013138717 A RU2013138717 A RU 2013138717A RU 2593756 C2 RU2593756 C2 RU 2593756C2
Authority
RU
Russia
Prior art keywords
trifluoromethyl
compound
furo
amino
tetrahydro
Prior art date
Application number
RU2013138717/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2013138717A (ru
Inventor
Адриан Холл
Кристофер Нил ФАРТИНГ
Пинейро Хосе Луис Кастро
Original Assignee
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43769479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2593756(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Publication of RU2013138717A publication Critical patent/RU2013138717A/ru
Application granted granted Critical
Publication of RU2593756C2 publication Critical patent/RU2593756C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2013138717/04A 2011-01-21 2012-01-20 Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе RU2593756C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1101140.0 2011-01-21
GBGB1101140.0A GB201101140D0 (en) 2011-01-21 2011-01-21 Fused aminodihydrothiazine derivatives
PCT/EP2012/050833 WO2012098213A1 (en) 2011-01-21 2012-01-20 Fused aminodihydrothiazine derivatives useful as bace inhibitors

Publications (2)

Publication Number Publication Date
RU2013138717A RU2013138717A (ru) 2015-02-27
RU2593756C2 true RU2593756C2 (ru) 2016-08-10

Family

ID=43769479

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013138717/04A RU2593756C2 (ru) 2011-01-21 2012-01-20 Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе

Country Status (21)

Country Link
US (3) US8338407B2 (uk)
EP (1) EP2665732B1 (uk)
JP (1) JP5947815B2 (uk)
KR (1) KR101906466B1 (uk)
CN (1) CN103328486B (uk)
AR (1) AR084903A1 (uk)
AU (1) AU2012208526B2 (uk)
BR (1) BR112013018602A2 (uk)
CA (1) CA2828738A1 (uk)
CL (1) CL2013002083A1 (uk)
ES (1) ES2575914T3 (uk)
GB (1) GB201101140D0 (uk)
IL (1) IL226596A (uk)
MX (1) MX2013007917A (uk)
PE (1) PE20141182A1 (uk)
RU (1) RU2593756C2 (uk)
SG (1) SG190908A1 (uk)
TW (1) TW201309710A (uk)
UA (1) UA109927C2 (uk)
WO (1) WO2012098213A1 (uk)
ZA (1) ZA201303801B (uk)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
RU2476431C2 (ru) 2008-01-18 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конденсированное производное аминодигидротиазина
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
JPWO2010047372A1 (ja) 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
US8569310B2 (en) 2009-10-08 2013-10-29 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
ES2624288T3 (es) 2011-01-21 2017-07-13 Eisai R&D Management Co., Ltd. Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
EP2763676B1 (en) * 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
US9618522B2 (en) * 2012-09-05 2017-04-11 Emory University Diagnostic testing in dementia and methods related thereto
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
WO2016149057A1 (en) * 2015-03-19 2016-09-22 Eli Lilly And Company Selective bace1 inhibitors
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
KR20170108203A (ko) * 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
US20190365774A1 (en) * 2016-08-18 2019-12-05 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
MX2019007104A (es) 2016-12-15 2019-11-05 Amgen Inc Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
JP7159161B2 (ja) 2016-12-15 2022-10-24 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
CN116143621A (zh) * 2022-12-14 2023-05-23 湖南农业大学 一种硼盐催化激活酰胺用于制备苯甲酸酯类化合物的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
EP2233474A1 (en) * 2008-01-18 2010-09-29 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
WO2011005738A1 (en) * 2009-07-09 2011-01-13 Eli Lilly And Company Bace inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235551A (en) 1966-02-15 Novel derivatives of
US3227713A (en) 1966-01-04 Azine derivatives
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
JP2003514910A (ja) 1999-11-24 2003-04-22 メルク エンド カムパニー インコーポレーテッド Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
KR100998804B1 (ko) 2002-05-03 2010-12-06 이스라엘 인스티튜트 포 바이올로지컬 리서치 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물,및 그에 유용한 신규 화합물
AU2003254844A1 (en) 2002-08-09 2004-02-25 Takeda Chemical Industries, Ltd. Substituted amino compounds and use thereof
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
WO2004043916A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
CN102627609B (zh) 2003-12-15 2016-05-04 默沙东公司 杂环天冬氨酰蛋白酶抑制剂
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US20070203147A1 (en) 2004-03-30 2007-08-30 Coburn Craig A 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
WO2006041404A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
JP2008516946A (ja) 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ−ピリミドンおよびそれらの使用
US8338614B2 (en) 2005-01-19 2012-12-25 Merck, Sharp & Dohme Corp. Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
EP2004630A4 (en) 2006-04-05 2010-05-19 Astrazeneca Ab 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
WO2007139230A1 (ja) 2006-05-31 2007-12-06 Asubio Pharma Co., Ltd. ７員環化合物並びにその製造法および医薬用途
EP2032542A2 (en) 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
AR071385A1 (es) 2008-04-22 2010-06-16 Schering Corp Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia.
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
AR073406A1 (es) 2008-09-30 2010-11-03 Eisai R&D Man Co Ltd Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
TWI464153B (zh) 2009-03-13 2014-12-11 Vitae Pharmaceuticals Inc β－分泌酶之抑制劑
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
CA2803009A1 (en) 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
ES2624288T3 (es) 2011-01-21 2017-07-13 Eisai R&D Management Co., Ltd. Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
EP2233474A1 (en) * 2008-01-18 2010-09-29 Eisai R&D Management Co., Ltd. Condensed aminodihydrothiazine derivative
WO2011005738A1 (en) * 2009-07-09 2011-01-13 Eli Lilly And Company Bace inhibitors

Also Published As

Publication number Publication date
US8338407B2 (en) 2012-12-25
GB201101140D0 (en) 2011-03-09
AR084903A1 (es) 2013-07-10
CL2013002083A1 (es) 2013-12-06
EP2665732A1 (en) 2013-11-27
US8592408B2 (en) 2013-11-26
US20130203740A1 (en) 2013-08-08
AU2012208526A1 (en) 2013-05-02
KR101906466B1 (ko) 2018-10-10
ES2575914T3 (es) 2016-07-04
ZA201303801B (en) 2014-07-30
AU2012208526B2 (en) 2015-09-24
IL226596A (en) 2016-04-21
KR20140002724A (ko) 2014-01-08
JP5947815B2 (ja) 2016-07-06
PE20141182A1 (es) 2014-09-14
EP2665732B1 (en) 2016-03-30
NZ611365A (en) 2015-04-24
JP2014502987A (ja) 2014-02-06
US20140142091A1 (en) 2014-05-22
TW201309710A (zh) 2013-03-01
SG190908A1 (en) 2013-07-31
BR112013018602A2 (pt) 2020-09-01
CA2828738A1 (en) 2012-07-26
RU2013138717A (ru) 2015-02-27
WO2012098213A1 (en) 2012-07-26
US8940734B2 (en) 2015-01-27
US20120190672A1 (en) 2012-07-26
CN103328486A (zh) 2013-09-25
MX2013007917A (es) 2013-08-29
UA109927C2 (uk) 2015-10-26
CN103328486B (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
RU2593756C2 (ru) Конденсированные производные аминодигидротиазина, пригодные в качестве ингибиторов васе
US9175013B2 (en) Fused aminodihydrothiazine derivatives
US9353084B2 (en) 2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer&#39;s disease
US10059669B2 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer&#39;s disease
JP2015514073A (ja) スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
US10004738B2 (en) Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
WO2014015125A1 (en) Fused aminodihydrothiazine derivative salts and uses thereof
GB2504615A (en) Fused aminodihydrothiazine derivatives
WO2017025565A1 (en) 2-amino-7a-phenyl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines as bace1 inhibitors
NZ611365B2 (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190121